Covid-19 vaccine may be ready by year-end, says WHO's Tedros Adhanom

We will need vaccines and there is hope that by the end of this year we may have a vaccine. There is hope, said WHO Director-General

WHO Director General Tedros Adhanom Ghebreyesus
WHO Director General Tedros Adhanom Ghebreyesus
Reuters Geneva
2 min read Last Updated : Oct 06 2020 | 8:08 PM IST
A vaccine against Covid-19 may be ready by year-end, the head of the World Health Organization (WHO) said on Tuesday, without elaborating.

WHO Director-General Tedros Adhanom Ghebreyesus called for solidarity and political commitment by all leaders to ensure equal distribution of vaccines when they become available.

"We will need vaccines and there is hope that by the end of this year we may have a vaccine. There is hope," Tedros said in closing remarks to the WHO's Executive Board meeting that examined the global response to the pandemic.

The EU health regulator has launched a real-time review of a Covid-19 vaccine developed by U.S. drugmaker Pfizer and Germany's BioNTech, it said on Tuesday, following a similar announcement for rival AstraZeneca's jab last week

. The announcement by the European Medicines Agency (EMA) could speed up the process of approving a successful vaccine in the bloc.

Nine experimental vaccines are in the pipeline of the WHO-led COVAX global vaccine facility that aims to distribute 2 billion doses by the end of 2021.

So far some 168 countries have joined the COVAX facility, but neither China, the United States nor Russia are among them.

The Trump administration has said it is relying instead on bilateral deals to secure supplies from vaccine makers.

"Especially for the vaccines and other products which are in the pipeline, the most important tool is political commitment from our leaders especially in the equitable distribution of the vaccines," Tedros said."We need each other, we need solidarity and we need to use all the energy we have to fight the virus," he said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineWorld Health Organization

Next Story